New Alzheimer s blood test predicts – “`html
New Alzheimer’s Blood Test Predicts Dementia Risk
A new Alzheimer’s blood test may soon help doctors identify individuals who are likely to develop dementia within five to ten years, even before any cognitive symptoms become apparent. According to research presented at the Alzheimer’s Association International Conference in London and published in The Journal of the American Medical Association, this simple blood draw could revolutionize how healthcare providers evaluate dementia risk in aging populations. By measuring a specific protein called p-tau217, which accumulates in the brain as Alzheimer’s disease progresses, clinicians could potentially screen for the condition much like they currently use cholesterol levels to assess cardiovascular health.
Study Findings Reveal Significant Predictive Power
The Harvard Medical School-led investigation followed nearly 2,700 adults who were cognitively healthy at the start, with an average age of 70 years. Over a follow-up period of up to ten years, scientists discovered that participants with very high concentrations of p-tau217 in their blood had approximately a 78 percent likelihood of developing cognitive impairment within a decade. For those with moderately elevated levels, the risk stood at around 45 percent over the same timeframe. Within a shorter five-year window, individuals with the highest biomarker levels faced roughly a one in three probability of experiencing cognitive decline.
The p-tau217 protein represents a modified version of tau, a substance that forms characteristic tangles in the brains of Alzheimer’s patients and correlates strongly with memory deterioration. Researchers noted that this blood-based approach delivers valuable information that complements traditional brain imaging techniques and genetic screening methods. Rachel Buckley, the study’s principal investigator and associate professor of neurology at Harvard Medical School, described the results as some of the most compelling evidence to date demonstrating that dementia susceptibility can be identified years before memory difficulties emerge.
“Once verified, these blood tests could be used to recruit patients for clinical trials of treatments to prevent cognitive decline and dementia,” Buckley explained in a press statement. “In the future, when treatments are approved for use early in the disease process, these tests could help guide monitoring, treatment decisions and counseling for patients and families.”
Despite the promising results, the research team emphasized that p-tau217 levels alone cannot definitively predict whether any single person will develop Alzheimer’s disease. Additional variables such as chronological age, genetic predisposition, kidney function, and racial background all contribute to biomarker concentrations and overall dementia susceptibility. Maria Carrillo, the chief science officer at the Alzheimer’s Association based in Chicago, highlighted that identifying individuals during the silent phase of the disease—before memory problems manifest—represents the most promising opportunity for future therapeutic interventions.
“Identifying people at risk earlier could fundamentally change how we diagnose, treat and potentially prevent dementia,” Carrillo told Fox News Digital, emphasizing that earlier detection enables people to start preventive measures before symptoms develop. The researchers stressed that additional long-term studies involving more diverse populations are necessary to refine these risk predictions further. As pharmaceutical companies develop new therapies targeting Alzheimer’s pathology, this new Alzheimer’s blood test could prove invaluable for selecting appropriate candidates for clinical trials and personalized treatment plans.
